Top

Published in:

Open Access 01-05-2015 | Glycogenoses

Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions

Authors: Terry G. J. Derks, Margreet van Rijn

Published in: Journal of Inherited Metabolic Disease | Issue 3/2015

Abstract

Hepatic glycogen storage diseases (GSD) underscore the intimate relationship between carbohydrate and lipid metabolism. The hyperlipidemias in hepatic GSD reflect perturbed intracellular metabolism, providing biomarkers in blood to monitor dietary management. In different types of GSD, hyperlipidemias are of a different origin. Hypertriglyceridemia is most prominent in GSD type Ia and associated with long-term outcome morbidity, like pancreatitis and hepatic adenomas. In the ketotic subtypes of GSD, hypertriglyceridemia reflects the age-dependent fasting intolerance, secondary lipolysis and increased mitochondrial fatty acid oxidation. The role of high protein diets is established for ketotic types of GSD, but non-traditional dietary interventions (like medium-chain triglycerides and the ketogenic diet) in hepatic GSD are still controversial and necessitate further studies. Patients with these rare inherited disorders of carbohydrate metabolism meet several criteria of the metabolic syndrome, therefore close monitoring for cardiovascular diseases in ageing GSD patients may be justified.

Bali DS, Chen YT, Goldstein JL (1993) Glycogen storage disease type I. In: Pagon RA, Adam MP, Ardinger HH et al (eds) GeneReviews(R). University of Washington, Seattle, Seattle

Bandsma RH, Prinsen BH, van Der Velden MS et al (2008) Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a. Pediatr Res 63:702–707CrossRefPubMed

Bernier AV, Sentner CP, Correia CE, Theriaque DW, Shuster JJ, Smit GP, Weinstein DA (2008) Hyperlipidemia in glycogen storage disease type III: effect of age and metabolic control. J Inherit Metab Dis 31:729–732CrossRefPubMed

Bernier AV, Correia CE, Haller MJ, Theriaque DW, Shuster JJ, Weinstein DA (2009) Vascular dysfunction in glycogen storage disease type I. J Pediatr 154:588–591CrossRefPubMedCentralPubMed

Bernstein LE, Bums CE, Wilkinson LJ, Boney A, Balliet J, Van Hove J (2010) Treatment of elevated triglycerides in glycogen storage disease type 1a and hypertriglyceridemia with medium chain triglycerides sources. J Inherit Metab Dis 33:S173–S173

Bier DM, Leake RD, Haymond MW, Arnold KJ, Gruenke LD, Sperling MA, Kipnis DM (1977) Measurement of “true” glucose production rates in infancy and childhood with 6,6-dideuteroglucose. Diabetes 26:1016–1023CrossRefPubMed

Brambilla A, Mannarino S, Pretese R, Gasperini S, Galimberti C, Parini R (2014) Improvement of cardiomyopathy after high-fat diet in two siblings with glycogen storage disease type III. JIMD Rep 17:91–95CrossRefPubMedCentralPubMed

Burns CE, Bernstein LE, Wilkinson LJ, Boney A, Myers S, Van Hove J (2009) Treatment of elevated triglycerides in glycogen storage disease type and hypertriglyceridemia with new medium chain triglycerides sources. Mol Genet Metab 98:56–57

Burr IM, O’Neill JA, Karzon DT, Howard LJ, Greene HL (1974) Comparison of the effects of total parenteral nutrition, continuous intragastric feeding, and portacaval shunt on a patient with type I glycogen storage disease. J Pediatr 85:792–795CrossRefPubMed

Chen YT, Cornblath M, Sidbury JB (1984) Cornstarch therapy in type I glycogen-storage disease. N Engl J Med 310:171–175CrossRefPubMed

Cuttino JT Jr, Summer GK, Hill HD Jr, Mitchell BJ (1970) Response to medium chain triglycerides in von Gierke’s disease. Pediatrics 46:925–929PubMed

Dagli A, Sentner CP, Weinstein DA (1993) Glycogen storage disease type III. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP (eds) GeneReviews. University of Washington, Seattle

Das AM, Lucke T, Meyer U, Hartmann H, Illsinger S (2010) Glycogen storage disease type 1: impact of medium-chain triglycerides on metabolic control and growth. Ann Nutr Metab 56:225–232CrossRefPubMed

Derks TG, Smit GP (2014) Dietary management in glycogen storage disease type III: what is the evidence? J Inherit Metab Dis. doi:10.1007/s10545-014-9756-x

Derks TG, Martens DH, Sentner CP, van Rijn M, de Boer F, Smit GP, van Spronsen FJ (2013) Dietary treatment of glycogen storage disease type Ia: uncooked cornstarch and/or continuous nocturnal gastric drip-feeding? Mol Genet Metab 109:1–2CrossRefPubMed

El-Gharbawy AH, Arnold GL, Perrott-Taylor N, Hughley T, Long K, Vockley J, Kishnani PS (2014) Optimizing metabolic control of glycogen storage disease type 3 (Gsd3): potential role for medium chain triglycerides (Mct). Mol Genet Metab 111:284–285

Fernandes J (1974) The effect of disaccharides on the hyperlacticacidaemia of glucose-6-phosphatase deficient children. Acta Paediatr Scand 63:695–698CrossRefPubMed

Fernandes J, Pikaar NA (1969) Hyperlipemia in children with liver glycogen disease. Am J Clin Nutr 22:617–627PubMed

Greene HL, Slonim AE, O’Neill JA Jr, Burr IM (1976) Continuous nocturnal intragastric feeding for management of type 1 glycogen-storage disease. N Engl J Med 294:423–425CrossRefPubMed

Grefhorst A, Schreurs M, Oosterveer MH et al (2010) Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor alpha (LXRalpha) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1. Biochem J 432:249–254CrossRefPubMed

Hanou CE, Wilkinson LJ, Bernstein LE (2008) Treatment of fatty acid oxidation disorders, glycogen storage disease type 1A and hypertriglyceridemia with new medium chain triglycerides sources. J Inherit Metab Dis 31:146–146

Hayde M, Widhalm K (1990) Effects of cornstarch treatment in very young children with type I glycogen storage disease. Eur J Pediatr 149:630–633CrossRefPubMed

Hershkovitz E, Rachmel A, Ben-Zaken H, Phillip M (2001) Continuous glucose monitoring in children with glycogen storage disease type I. J Inherit Metab Dis 24:863–869CrossRefPubMed

Huidekoper HH, Visser G, Ackermans MT, Sauerwein HP, Wijburg FA (2010) A potential role for muscle in glucose homeostasis: in vivo kinetic studies in glycogen storage disease type 1a and fructose-1,6-bisphosphatase deficiency. J Inherit Metab Dis 33:25–31CrossRefPubMedCentralPubMed

Huidekoper HH, Ackermans MT, Ruiter AF, Sauerwein HP, Wijburg FA (2014) Endogenous glucose production from infancy to adulthood: a non-linear regression model. Arch Dis Child 99:1098–1102CrossRefPubMed

Kasapkara ÇS, Cinasal Demir G, Hasanoğlu A, Tümer L (2014) Continuous glucose monitoring in children with glycogen storage disease type I. Eur J Clin Nutr 68:101–105CrossRefPubMed

Kelsch RC, Oliver WJ (1969) Studies on dietary correction of metabolic abnormalities in hepatorenal glycogenosis. Pediatr Res 3:160–170CrossRefPubMed

Laforêt P, Weinstein DA, Smit GPA (2011) The glycogen storage diseases and related disorders, chap 6. In Saudubray JM, van den Berghe G, Walter J (eds). Inborn metabolic diseases. Springer, Berlin

Moses SW (2002) Historical highlights and unresolved problems in glycogen storage disease type 1. Eur J Pediatr 161:S2–S9CrossRefPubMed

Nagasaka H, Hirano K, Ohtake A et al (2007) Improvements of hypertriglyceridemia and hyperlacticemia in Japanese children with glycogen storage disease type Ia by medium-chain triglyceride milk. Eur J Pediatr 166:1009–1016CrossRefPubMed

Oosterveer MH, Schoonjans K (2014) Hepatic glucose sensing and integrative pathways in the liver. Cell Mol Life Sci 71:1453–1467CrossRefPubMed

Rajas F, Labrune P, Mithieux G (2013) Glycogen storage disease type 1 and diabetes: learning by comparing and contrasting the two disorders. Diabetes Metab 39:377–387CrossRefPubMed

Rajas F, Clar J, Gautier-Stein A, Mithieux G (2014) Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease. J Inherit Metab Dis. doi:10.1007/s10545-014-9761-0 PubMed

Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP (2002a) Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European study on glycogen storage disease type I (ESGSD I). Eur J Pediatr 161(Suppl 1):S20–S34CrossRefPubMed

Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP, European Study on Glycogen Storage Disease Type I (ESGSD I) (2002b) Guidelines for management of glycogen storage disease type I - European study on glycogen storage disease type I (ESGSD I). Eur J Pediatr 161(Suppl 1):S112–S119CrossRefPubMed

Shah KK, O’Dell SD (2013) Effect of dietary interventions in the maintenance of normoglycaemia in glycogen storage disease type 1a: a systematic review and meta-analysis. J Hum Nutr Diet 26:329–339CrossRefPubMed

Smit GP, Berger R, Potasnick R, Moses SW, Fernandes J (1984) The dietary treatment of children with type I glycogen storage disease with slow release carbohydrate. Pediatr Res 18:879–881CrossRefPubMed

Ubels FL, Rake JP, Slaets JP, Smit GP, Smit AJ (2002) Is glycogen storage disease 1a associated with atherosclerosis? Eur J Pediatr 161(Suppl 1):S62–S64CrossRefPubMed

Valayannopoulos V, Bajolle F, Arnoux J et al (2011) Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D, L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res 70:638–641CrossRefPubMed

van Dijk TH, van der Sluijs FH, Wiegman CH et al (2001) Acute inhibition of hepatic glucose-6-phosphatase does not affect gluconeogenesis but directs gluconeogenic flux toward glycogen in fasted rats. A pharmacological study with the chlorogenic acid derivative S4048. J Biol Chem 276:25727–25735CrossRefPubMed

Wang DQ, Fiske LM, Carreras CT, Weinstein DA (2011) Natural history of hepatocellular adenoma formation in glycogen storage disease type I. J Pediatr 159:442–446CrossRefPubMedCentralPubMed

White FJ, Jones SA (2011) The use of continuous glucose monitoring in the practical management of glycogen storage disorders. J Inherit Metab Dis 34:631–642CrossRefPubMed

Xue J, Chen H, Xiong D, Huang G, Ai H, Liang Y, Yan X, Gan Y, Chen C, Chao R, Ye L (2014) Noninvasive measurement of glucose in artificial plasma with near-infrared and Raman spectroscopy. Appl Spectrosc 68:428–433CrossRefPubMed

Title: Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions
Authors: Terry G. J. Derks
Margreet van Rijn
Publication date: 01-05-2015
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 3/2015
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-015-9811-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease

The spectrum of pyruvate oxidation defects in the diagnosis of mitochondrial disorders

Dietary management in glycogen storage disease type III: what is the evidence?

Exercise in muscle glycogen storage diseases

Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency: urinary organic acid profiles and expanded spectrum of mutations

Christian Körner

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page